Shots:
- The US FDA has granted 510(k) clearance to the next-generation Metrix COVID Test, with development supported by BARDA. The test is cleared for OTC and professional use in CLIA-waived settings
- The handheld molecular test delivers approximately 3-fold higher analytical sensitivity & 30% faster results than EUA-authorized product, targeting urgent care & other decentralized settings
- Aptitude is expanding the Metrix molecular diagnostics platform, with its COVID/Flu test under FDA review and additional products for RSV, Strep, and sexually transmitted infections in late-stage development or under FDA review
Ref: PRnewswire | Image: Aptitude | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
